No association found between thiazolidinediones and bladder cancer
the ONA take:
According to a new study published in the journal Diabetologia, there is no link between either pioglitazone or rosiglitazone and bladder cancer.
For the study, the researchers collected prescription, cancer, and mortality data from 1.01 million people with type 2 diabetes from six populations in Europe and North America. Of those, 3,248 developed bladder cancer and only 117 of those were in patients who had taken pioglitazone.
Results showed that there was no link between cumulative exposure to the thiazolidinediones and bladder cancer in men or women after adjustment for other factors. In addition, longer exposure to pioglitazone did no increase the risk for developing bladder cancer.
According to the American Cancer Society, there will be an estimated nearly 75,000 new cases of bladder cancer and about 15,600 deaths from the disease. Men are about 3 to 4 times more likely to develop bladder cancer than women, but that risk is about 1 in 26 men.
Previous studies have shown that drugs from this class of antidiabetic drugs increases the risk of bladder cancer, but this study demonstrates otherwise. The authors suggest that studies with a longer duration of follow-up of patients exposed to pioglitazone or rosiglitazone be conducted to end the controversy.
There is no link between either pioglitazone or rosiglitazone and bladder cancer.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|